MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
EXAS stock logo

EXAS

Exact Sciences Corporation

$104.91
0
 (0%)
[ms_data_label text=’Delayed data’]
Exchange:  NASDAQ
Market Cap:  20.026B
Shares Outstanding:  588143
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Diagnostics & Research
   
CEO:  Kevin T. Conroy
Full Time Employees:  6900
Address: 
5505 Endeavor Lane
Madison
WI
53719
US
Website:  https://www.exactsciences.com
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company’s pipeline products focus on enhancing the Cologuard test’s performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/01 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue2,499,7662,758,8673,246,990
Gross Profit1,762,1661,918,6672,262,839
EBITDA29,283-789,328122,500
Operating Income-215,012-1,048,703-99,079
Net Income-204,149-1,028,857-207,949

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets6,471,3345,928,1395,860,629
Total Liabilities3,326,0293,525,8903,459,577
Total Stockholders Equity3,145,3052,402,2492,401,052
Total Debt2,554,7252,754,7582,522,699
Cash and Cash Equivalents605,378600,889955,996

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow156,119210,536491,438
Capital Expenditure-124,190-135,989-134,656
Free Cash Flow31,92974,547356,782
Net Income-204,149-1,028,857-207,949
Net Change in Cash366,885-3,039349,360

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)4,747,256.511Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)5,322,914.796Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)5,123,972.450Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)1,422,092.548Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)1,594,537.276Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)1,534,941.923Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)534,147.427Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)620,402.373Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)590,593.443Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)3,375,702.620Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)3,785,044.558Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)3,643,579.652Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)3.130Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)3.290Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)2.830Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)6Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
2.759B  ?P/S
 (TTM)
: 
6.17
?Net Income
 (TTM)
: 
-1028857000  ?P/E
 (TTM)
: 
-95.72
?Enterprise Value
 (TTM)
: 
21.593B  ?EV/FCF
 (TTM)
: 
60.52
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.09  ?ROIC
 (TTM)
: 
-0.04
?Net Debt
 (TTM)
: 
1.738B  ?Debt/Equity
 (TTM)
: 
1.05
?P/B
 (TTM)
: 
8.29  ?Current Ratio
 (TTM)
: 
2.23

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates EXAS intrinsic value between $5.71 – $5.96 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate EXAS Intrinsic Value

Common questions about EXAS valuation

Is EXAS (EXAS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for EXAS (EXAS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is EXAS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether EXAS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is EXAS’s P/E ratio?

You can see EXAS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for EXAS?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is EXAS a good long-term investment?

Whether EXAS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

EXAS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

0
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low:    Year High: 
Price Avg 50:    Price Avg 200: 
Volume:    Average Volume: 

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Banque Pictet & Cie SA Lowers Position in Exact Sciences Corporation $EXAS
Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
Exact Sciences Stockholders Approve Acquisition by Abbott
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up
Exact Sciences Corporation $EXAS Shares Sold by AlphaQuest LLC

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read